2025-05-12 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate…
